top of page

Campaign for Personal Prescription Importation

1220 L Street NW Suite 100 Washington, DC 20005

info@personalimportation.org

Happy old Vietnamese couple hugging outdoor

OUR BLOGS

#BIGPHARMA SETS LOBBYING SPENDING RECORD

Apr 23, 2018
1 min

#BIGPHARMA SETS LOBBYING SPENDING RECORD

Breaking records is a good thing when you are an Olympic athlete, but breaking records is not a good thing when your goal is to keep #RxPrices high for hard-working Americans. So, when the news that #BigPharma has broken several quarterly lobbying spending records so far in 2018, we heaved a sigh of grief. Nearly $10 million has been spent trying to block efforts to lower the outrageous cost of medications, including trying to block generic companies from studying their produ

1 view0 comments

Mar 23, 2018
1 min

NEW POLL ON AMERICANS’ VIEWS ON DRUG PRICING

Today, Kaiser Health release new data showing more than half of the public – 52% – believe that passing legislation to bring down #RxPrices should be a top priority for President Trump and Congress, yet less than half the public – 39% – say they are confident that they will be able to deliver on the promise to lower prescription drug prices. The survey also revealed that 72% of Americans say #BigPharma has too much influence on lawmakers, more than even the National Rifle Ass

0 views0 comments

STATES TAKE UP FIGHT TO LOWER RX PRICES

Feb 15, 2018
2 min

STATES TAKE UP FIGHT TO LOWER RX PRICES

In recent weeks, an astonishing number of states have taken up the fight against #BigPharma to lower prescription drug prices. In fact, two-thirds of states are currently considering proposals that would make medications more affordable, and many of these states are looking at personal prescription importation from licensed, legitimate online pharmacies in Canada as one possible solution. According to the National Academy for State Health Policy, a whopping 87 bills in 34 sta

0 views0 comments

VOTERS: REDUCING #RXPRICING A KEY PRIORITY

Feb 6, 2018
1 min

VOTERS: REDUCING #RXPRICING A KEY PRIORITY

A new poll shows that more than 85 percent of voters believe that lowering drug prices should be a key priority for Congress. The poll, conducted by GS Strategy Group, also showed that about 75 percent of those surveyed said that Congress needed to do more about high drug prices. We agree! Americans have been carrying the burden of skyrocketing pharmaceutical prices for far too long – and not enough is being done to change the situation. #BigPharma has been given free rein to

0 views0 comments

NEW YEAR, SAME OLD BIG PHARMA

Jan 10, 2018
2 min

NEW YEAR, SAME OLD BIG PHARMA

New Year’s Day is the day that Big Pharma companies announce their price increases, and instead of a fresh new start to the year many decided to go back to their same old tricks. One company in particular – Allergan Inc. – has had a particularly troublesome track record of high price increases disgraces. This is the company that transferred the patent rights on one of its key products to a Native American tribe to extend the life of the patent and thereby maintain pricing con

2 views0 comments

#BIGPHARMA GEARING UP FOR A BIG WIN

Jan 9, 2018
1 min

#BIGPHARMA GEARING UP FOR A BIG WIN

Department of Health and Human Services (HHS) Secretary-Nominee Alex Azar’s Confirmation Hearing was yet another slap in the face for America’s patients who need access to safe and affordable prescription medications. Numerous Senators raised red flags around Azar’s actions during his tenure at Eli Lilly & Company, which includes dramatically increasing the prices for several medications that resulted in huge profits for the company. When Senator Ron Wyden (D-OR) repeatedly a

0 views0 comments

Nov 30, 2017
2 min

HHS SECRETARY NOMINEE SHOWS HIS TRUE COLORSOn Wednesday, the Senate Health Education Labor and Pensi

On Wednesday, the Senate Health Education Labor and Pensions Committee held a hearing on the nomination of Alex Azar to be Secretary of Health and Human Services, which oversees the Medicare and Medicaid programs. Azar is the current poster child for #BadPharma behavior, leveraging the revolving door between government and the corporate world to serve his best interests and game the system, which he repeatedly cited as the problem although his track record of taking advantage

0 views0 comments

BIG PHARMA: MARKET FAILURE

Nov 16, 2017
1 min

BIG PHARMA: MARKET FAILURE

This new video – Big Pharma: Market Failure – looks at the impact of outrageous drug prices in the U.S. on the public, businesses and overall economy. This in-depth look at the problem of high priced #pharmaceuticals helps put this into perspective, there is nothing stopping #BigPharma from charging whatever they want for medications regardless of their value. The typical #BigPharma arguments are explored and discredited. As they waive the banner for being champions of resea

0 views0 comments

REVOLVING DOOR CONTINUES TO REVOLVE

Nov 14, 2017
2 min

REVOLVING DOOR CONTINUES TO REVOLVE

Earlier this month, seven senators introduced legislation to slow the revolving door between federal agencies and the pharmaceutical companies that those agencies are charged with regulating. Fast forward to yesterday, President Donald Trump officially nominates Alex Azar – former president of one of the largest #BigPharma companies in the world – to lead the Department of Health and Human Services (HHS), which is responsible for overseeing healthcare and federal public healt

0 views0 comments

SAFETY IS NOT A DEBATE

Oct 24, 2017
1 min

SAFETY IS NOT A DEBATE

Big Pharma resists any efforts to lower prescription drug prices by raising fears over safety. Since fear is a powerful motivator, it can be effective. But safety is not a matter of debate, a drug is either safe or it is not. Today, the Canadian International Pharmacy Association issued this press release citing a 100% perfect safety record for personal prescription importation from licensed, certified and trusted retail pharmacies for the past 15 years, at 50-80 percent less

0 views0 comments

THE ATLANTIC FORUM ON RX DRUGS: AT WHAT COST?

Oct 3, 2017
2 min

THE ATLANTIC FORUM ON RX DRUGS: AT WHAT COST?

Today, we attended an event hosted by The Atlantic focused on the high cost of pharmaceuticals – At What Cost? It will come as no surprise that the inside-the-beltway policy debate around access to prescription medications continues to be mired in half-truths and finger-pointing blame games but the bottom line remains the same – Americans pay more for prescription drugs than any other country in the world. The event was well-attended – interest in the issue remains high – and

0 views0 comments

FIGHTING THE GOOD FIGHT

Sep 26, 2017
1 min

FIGHTING THE GOOD FIGHT

In countless media stories, highly questionable and aggressive tactics of the #BigPharma lobby have been exposed. It is no secret that lawmakers are being pressured and manipulated by an army of lobbyists with deep pockets. In fact, #BigPharma lobbying spending has already surpassed $145 million in the first half of 2017, according to the Center for Responsive Politics. While the ads paint a pretty picture of caring about patients, in reality #BigPharma uses its heavy influen

0 views0 comments

PATIENT ASSISTANCE PROGRAMS HELP BIG PHARMA MORE THAN PATIENTS

Aug 17, 2017
1 min

PATIENT ASSISTANCE PROGRAMS HELP BIG PHARMA MORE THAN PATIENTS

David Lazarus, in this LA Times story, exposes questionable practices of #BigPharma to appear to care about patients through Patient Assistance Programs that on the surface seem to subsidize the cost of exorbitantly priced #pharmaceuticals. Yet the reality is that these programs often fall flat in helping patients, but can be helpful in arming pharma companies with slick promotions on how they are helping consumers afford their medications. As we have seen time and again from

0 views0 comments

BLOWING UP BIG PHARMA’S R&D CLAIMS

Jul 13, 2017
1 min

BLOWING UP BIG PHARMA’S R&D CLAIMS

#BigPharma claims that they need to maintain the high price of #pharmaceuticals in order to fund research and development for future cures and treatments. Don’t believe the hype! New data compares the amount of spending on R&D compared to prescription drug sales among the top ten #BigPharma companies. Here’s the reality: #BigPharma spends a fraction of revenue generated from prescription drug sales on R&D. Check out this chart from the Pharmaceutical Executive: http://read.bi

0 views0 comments

Jun 13, 2017
2 min

SENATE HEARING ON HIGH COST OF PRESCRIPTION DRUGS

Today, the Senate Health, Education, Labor and Pensions Committee held a hearing on the high cost of prescription drugs, which is the first in a series of three hearings on this topic. The underlying theme of the hearing was the lack of debate and closed door secrecy around the impending vote on repealing and replacing the Affordable Care Act, which would affect insurance coverage for millions of Americans. Senators from both parties expressed support for personal prescriptio

0 views0 comments

Jun 2, 2017
1 min

READ BETWEEN THE LINES

When was the last time that you went to pick up your medication and negotiated what you pay the pharmacy? Negotiating prices between pharma companies and payers is common practice. Yet consumers are still not seeing enough benefit from the rebates based on these negotiations. This op-ed from the Pharmaceutical Research and Manufacturer of America’s President and CEO advices that the reason Americans are struggling to pay for their medication is that the system is flawed, but

1 view0 comments

May 15, 2017
1 min

VOX: INSULIN DRUG PRICES TELL US A LOT ABOUT WHAT’S WRONG WITH DRUG PRICING IN AMERICA

Julia Belluz, in this Vox article, recalls a very different pricing strategy for prescription drugs – Doctors who refused to patent the discovery of insulin in 1923 and sold the patent to the University of Toronto for $1 because they wanted everyone who needed their medication to be able to afford it. On May 2, Eli Lilly raised the price of its insulin medications by 7.8 percent, according to CNBC’s Meg Tirrell. Eli Lilly is not alone, Sanofi and Novo Nordisk have also increa

0 views0 comments

Apr 19, 2017
1 min

BLOOMBERG: HOW DRUG-COMPANY ‘BENEVOLENCE’ SILENCES THE SICK

Bloomberg columnist Joe Nocera exposes questionable practices of a #BigPharma company in claiming a partnership with a patient advocacy group, although the group never formally agreed to engage in a partnership with the company. Is this an isolated example of a dubious ‘partnership’ approach employed by #BigPharma? We don’t think so. Of particular note in this piece is the role of a patient to advocate and engage on an issue that was important to him and others like him, and

0 views0 comments

bottom of page